share_log

Delivra Health Brands Announces Closing of Non-Brokered Private Placement of Units

Delivra Health Brands Announces Closing of Non-Brokered Private Placement of Units

Delivra Health Brands宣佈關閉非經紀私募單位
newsfile ·  2023/12/13 05:33

Vancouver, British Columbia--(Newsfile Corp. - December 12, 2023) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) ("Delivra Health" or the "Company"), a consumer packaged goods company uniquely positioned in the health and wellness sector, is pleased to announce the closing of its non-brokered private placement (the "Offering") of units (the "Units") previously announced on December 1, 2023. The Company issued a total of 60,000,000 Units at a price of $0.015 per Unit for aggregate gross proceeds of $900,000. Each Unit is comprised of one common share of the Company ("Common Share") and one Common Share purchase warrant (each, a "Warrant"). Each Warrant will entitle the holder thereof to acquire one Common Share (each, a "Warrant Share") at a price of $0.05 per Warrant Share for 36 months following the completion of the Offering.

不列顛哥倫比亞省溫哥華--(Newsfile Corp.,2023 年 12 月 12 日)-Delivra Health Brands Inc.(多倫多證券交易所:DHB)(OTCQB:DHBUF)(”德利維拉健康“或者”公司“) 是一家在健康和保健領域具有獨特地位的包裝消費品公司,很高興地宣佈其非經紀私募配售(”提供“) 的單位 (”單位“) 此前已於 2023 年 12 月 1 日宣佈。該公司以每單位0.015美元的價格發行了總計6000萬套單位,總收益爲90萬美元。每個單位由公司的一股普通股組成(”普通股“) 和一份普通股購買認股權證(每份,一份”搜查令“)。每份認股權證將授權其持有人購買一股普通股(每股,a”認股權證“) 在發行完成後的36個月內,每股認股權證的價格爲0.05美元。

The Company intends to use the net proceeds of the Offering for working capital and general corporate purposes and to support its ongoing marketing initiatives to support its distribution and customer acquisition strategy. All securities issued pursuant to the Offering are subject to a hold period of four months plus a day from the date of issuance prescribed by the TSX Venture Exchange (the "TSX-V") and the resale rules of applicable securities legislation. In connection with the Offering, the Company incurred cash finder's fees of $18,459 on gross proceeds raised by eligible arm's length parties.

公司打算將本次發行的淨收益用於營運資金和一般公司用途,並支持其正在進行的營銷活動以支持其分銷和客戶獲取戰略。根據本次發行發行的所有證券的持有期均爲四個月加自多倫多證券交易所風險交易所規定的發行之日起一天(即TSX-V“)以及適用的證券立法的轉售規則。在本次發行中,公司從符合條件的正常交易方籌集的總收益中收取了18,459美元的現金髮現費。

Certain insiders of the Company (the "Insiders") participated in the Offering and acquired an aggregate of 35,820,000 Units. Such subscriptions by the Insiders constitute a related party transaction under Multilateral Instrument 61-101 - Protection of Security Holders in Special Transactions ("MI 61-101"). However, any such purchase is exempt from the formal valuation and minority approval requirements of MI 61-101 by virtue of the exemptions contained in sections 5.5(b) and 5.7(1)(b) of MI 61-101, and where there is no other requirement, corporate or otherwise, to hold a meeting to obtain any approval of the holders of any class of affected securities. Pursuant to MI 61-101, the Company will file a material change report providing disclosure in relation to each "related party transaction" on SEDAR+ under Delivra Health's issuer profile at . The Company did not file a material change report more than 21 days before the expected closing date of the Offering as required by MI 61-101, because the timing of the announcement and the closing date was less than 21 days apart.

該公司的某些內部人士(“內部人士“) 參與了本次發行,共收購了35,820,000套單位。根據61-101號多邊文書,內幕人士的此類認購構成關聯方交易- 在特殊交易中保護證券持有人 (”MI 61-101“)。但是,根據MI 61-101第5.5(b)和5.7(1)(b)節中包含的豁免,任何此類收購均不受MI 61-101的正式估值和少數股權批准要求的約束,並且在沒有其他公司或其他要求的情況下,舉行會議以獲得任何類別的受影響證券持有人的批准。根據MI 61-101,公司將提交一份重大變更報告,在Delivra Health的發行人簡介下披露與SEDAR+上每筆 “關聯方交易” 有關的信息,網址爲。公司沒有按照MI 61-101的要求在發行的預期截止日期前超過21天提交重大變更報告,因爲公告的時間和截止日期相隔不到21天。

The securities referred to in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold within the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulation S under the U.S. Securities Act) absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release shall not constitute an offer to sell or the solicitation of any offer to buy, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

本新聞稿中提及的證券尚未根據經修訂的1933年《美國證券法》進行註冊(”《美國證券法》“),未經註冊或未獲得《美國證券法》和適用的美國州證券法註冊要求的適用豁免,不得在美國境內發行或出售,也不得向美國人(定義見《美國證券法》第S條例)或爲其賬戶或利益進行發行或出售。本新聞稿不應構成出售要約或招攬任何買入要約,也不得在任何非法的司法管轄區出售證券。

About Delivra Health Brands Inc.

關於 Delivra 健康品牌公司

Helping people take control of their health with alternative wellness solutions is what energizes the Delivra Health team! The Delivra Health portfolio features innovative brands like Dream Water and LivRelief, which deliver relief from common everyday issues like chronic pain, anxiety, and sleeplessness. Delivra Health products have allowed millions of customers to reclaim their mobility, energy, and in turn, quality of life. The websites of the Company's two subsidiaries are Dream Water and LivReliefTM. For more information, please visit .

通過替代健康解決方案幫助人們控制自己的健康是Delivra Health團隊的動力!Delivra Health產品組合以Dream Water和LivRelief等創新品牌爲特色,這些品牌可以緩解慢性疼痛、焦慮和失眠等常見的日常問題。Delivra Health 產品使數百萬客戶能夠回收他們的出行能力、能源,進而提高生活質量。該公司兩家子公司的網站是 Dream Water 和 LivReliefTM。欲了解更多信息,請訪問。

Cautionary Note Regarding Forward-Looking Statements

關於前瞻性陳述的警示說明

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements include, among other things, statements with respect to the use of proceeds from the Offering.

本新聞稿包含適用的加拿大證券立法所指的 “前瞻性信息” 和 “前瞻性陳述”(統稱爲 “前瞻性陳述”)。除歷史事實陳述外,所有陳述均爲前瞻性陳述,基於截至本新聞稿發佈之日的預期、估計和預測。任何涉及預測、預期、信念、計劃、預測、目標、假設、未來事件或績效的討論的陳述(通常但不總是使用諸如 “期望”、“不期望”、“預期” 或 “未預期”、“計劃”、“預算”、“預期”、“預測”、“估計”、“相信” 或 “打算” 之類的詞語或此類詞語的變體)以及指明某些行動、事件或結果 “可能”、“會”、“可能” 或 “將” 付諸實施或實現的短語)不是陳述歷史事實,可能是前瞻性陳述。在本新聞稿中,前瞻性陳述除其他外包括與本次發行收益的使用有關的陳述。

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the cannabis markets where the Company operates; changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; employee relations and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution, and sale of cannabis and cannabis-related products in the markets where the Company operates. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

這些前瞻性陳述基於發表此類陳述時公司管理層的合理假設和估計。未來的實際業績可能存在重大差異,因爲前瞻性陳述涉及已知和未知的風險、不確定性和其他因素,這些因素可能導致公司的實際業績、業績或成就與此類前瞻性陳述所表達或暗示的任何未來業績、業績或成就存在重大差異。這些因素包括:總體宏觀經濟狀況的波動;證券市場的波動;對公司經營的大麻市場規模的預期;消費者習慣的改變;公司成功實現業務目標的能力;擴張計劃;政治和社會不確定性;無法獲得足夠的保險來承保風險和危險;員工關係以及可能限制種植、生產、分銷的法律和法規的存在,以及在公司經營的市場上銷售大麻和大麻相關產品。儘管本新聞稿中包含的前瞻性陳述基於公司管理層當時認爲或認爲的合理假設,但公司無法向股東保證實際業績將與此類前瞻性陳述一致,因爲可能還有其他因素導致業績與預期、估計或預期不符。讀者不應過分依賴本新聞稿中包含的前瞻性陳述和信息。除非法律要求,否則公司沒有義務在信念、觀點、預測或其他因素的前瞻性陳述發生變化時對其進行更新。

Additional information regarding this and other risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's annual information form dated March 2, 2021, and under the heading "Risks and Uncertainties" in the Company's management's discussion and analysis dated October 18, 2023 for fiscal 2023 filed under the Company's profile on SEDAR+ at .

有關該風險以及與公司業務有關的其他風險和不確定性的其他信息載於公司2021年3月2日年度信息表中的 “風險因素” 標題下,以及公司管理層於2023年10月18日在SEDAR+公司簡介下提交的2023財年討論和分析中的 “風險和不確定性” 標題下。

Neither TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accept responsibility for the adequacy or accuracy of this release.

TSX-V 及其監管服務提供商(該術語在 TSX-V 的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

Investor Relations:
Jack Tasse
Chief Financial Officer
IR@delivrahealth.com
1-877-915-7934

投資者關係:
傑克·塔斯
首席財務官
IR@delivrahealth.com
1-877-915-7934

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES.

不用於向美國新聞通訊社發行或直接或間接、全部或部分在美國境內或向美國發行、出版、發行或傳播。

To view the source version of this press release, please visit

要查看本新聞稿的源版本,請訪問

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論